Arcellx (ACLX)
(Delayed Data from NSDQ)
$76.20 USD
-0.03 (-0.04%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $76.16 -0.04 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$76.20 USD
-0.03 (-0.04%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $76.16 -0.04 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Zacks News
Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arcellx (ACLX) delivered earnings and revenue surprises of 5.56% and 1.23%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Gilead Sciences (GILD) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 24.84% and 4.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Alkermes (ALKS) Lags Q2 Earnings Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of -1.37% and 1.21%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcellx (ACLX) delivered earnings and revenue surprises of 72.55% and 32.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 763.64% and 10.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
How Arcellx (ACLX) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Arcellx (ACLX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Arcellx, Inc. (ACLX) delivered earnings and revenue surprises of 166.67% and 163.52%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Gilead (GILD), Compugen Collaborate for Immunotherapy Program
by Zacks Equity Research
Gilead (GILD) enters into a license agreement with Compugen for its pre-clinical immunotherapy program.
The Zacks Analyst Blog Highlights Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics
by Zacks Equity Research
Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics are included in this Analyst Blog.
Biotech Stock Roundup: BMY's Drug Approval, VRTX & CRSP Gene Therapy Get MHRA Nod
by Zacks Equity Research
Bristol Myers (BMY) and Vertex (VRTX) drug approvals are in focus in the biotech sector.
Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead
by Zacks Equity Research
Arcellx (ACLX) and Gilead (GILD) expand their existing collaboration in cancer treatment. This deal is expected to close by year-end.
Is a Surprise Coming for Arcellx (ACLX) This Earnings Season?
by Zacks Equity Research
Arcellx (ACLX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
by Ekta Bagri
Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.
Roblox (RBLX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Roblox's (RBLX) third-quarter 2023 performance is expected to have benefited from growth in engagement hours and daily active users.
Take-Two (TTWO) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Take-Two's (TTWO) fiscal second-quarter performance is expected to have been dented by rising operating expenses despite portfolio strength.
What Awaits Warner Bros. Discovery (WBD) in Q3 Earnings?
by Zacks Equity Research
Warner Bros. Discovery's (WBD) third-quarter results are likely to reflect slow advertising revenues and subscriber growth in viewership amid cost-cutting measures.
Disney (DIS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Disney's (DIS) fiscal fourth-quarter results are expected to reflect declining Disney+ subscriber growth rate amid stiff competition.
Are Medical Stocks Lagging Arcellx (ACLX) This Year?
by Zacks Equity Research
Here is how Arcellx, Inc. (ACLX) and Ardelyx (ARDX) have performed compared to their sector so far this year.
Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Arcellx, Inc. (ACLX) and BellRing Brands (BRBR) have performed compared to their sector so far this year.
Wall Street Analysts Believe Arcellx, Inc. (ACLX) Could Rally 35.56%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 35.6% in Arcellx, Inc. (ACLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
5 Biotech Stocks to Buy as New Drug Approvals Drive Industry Prospects
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position EXEL, DVAX, ACLX, ANIP and VNDA well amid volatility.
Gilead's (GILD) Leukemia Study Progress Put on Clinical Hold
by Zacks Equity Research
Gilead (GILD) faces a setback as the FDA puts a partial clinical hold on enrolling new patients in studies evaluating magrolimab for treating AML in the United States.
Does Arcellx, Inc. (ACLX) Have the Potential to Rally 39.12% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 39.1% in Arcellx, Inc. (ACLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies
by Zacks Equity Research
Gilead (GILD) enters into a deal with Tentarix Biotherapeutics to discover and develop novel therapies for cancer and inflammation.
Gilead (GILD) Ends Myelodysplastic Syndromes Study on Magrolimab
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) discontinues phase III ENHANCE study, evaluating the potential of magrolimab as a treatment for higher-risk myelodysplastic syndromes, due to futility based on a planned analysis.